U.S., Nov. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07229313) titled 'A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors' on Sept. 16.
Brief Summary: This is a 2-part, first-in-human, open-label study to determine the safety and tolerability and preliminary efficacy of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
Study Start Date: Nov. 15
Study Type: INTERVENTIONAL
Condition:
Endometrial Cancer
Ovarian Cancer (OvCa)
Breast Cancer
Cervical Cancer
Esophageal Squamous Cell Cancer
Colorectal Cancer
Pancreatic Cancer
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Head and Neck Squamous Cell Carc...